News Releases
Board of Directors Authorizes Share Repurchase Program
“In the third quarter,
Third Quarter 2018 Financial Results
Revenue was
Gross profit was
Operating expenses were
Operating income was
Net income was
Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, of
See the “Non-GAAP Financial Measure – Adjusted EBITDA” section of this release for a reconciliation of Adjusted EBITDA to Net Income Attributable to
Share Repurchase Program
Ultralife’s Board of Directors has authorized the repurchase of up to 2.5 million shares of the Company’s common stock over a period not to exceed twelve months. Share repurchases, if any, will be made in accordance with SEC Rule 10b-18 using a variety of methods, which may include open market purchases, privately negotiated transactions or block trades, or any combination of such methods, in accordance with applicable insider trading and other securities laws and regulations.
The timing and actual number of shares repurchased will depend on a variety of factors including price, market conditions and applicable legal requirements. The share repurchase program does not obligate the Company to repurchase any specific number of shares and may be suspended or terminated at any time without prior notice.
About
Headquartered in
Conference Call Information
This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in revenues from key customers, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s
ULTRALIFE CORPORATION AND SUBSIDIARIES | |||
CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) |
|||
(Unaudited) | |||
ASSETS | |||
September 30, 2018 |
December 31, 2017 |
||
Current Assets: | |||
Cash | $25,454 | $18,330 | |
Trade Accounts Receivable, Net | 14,533 | 14,657 | |
Inventories | 23,118 | 26,326 | |
Prepaid Expenses and Other Current Assets | 2,900 | 2,603 | |
Total Current Assets | 66,005 | 61,916 | |
Property, Equipment and Improvements, Net | 8,792 | 7,570 | |
Goodwill, Intangibles and Other Assets | 26,999 | 27,700 | |
Total Assets | $101,796 | $97,186 | |
LIABILITIES AND SHAREHOLDERS' EQUITY | |||
Current Liabilities: | |||
Accounts Payable | $7,260 | $8,787 | |
Accrued Compensation and Related Benefits | 1,641 | 2,413 | |
Accrued Expenses and Other Current Liabilities | 3,463 | 3,039 | |
Total Current Liabilities | 12,364 | 14,239 | |
Deferred Income Taxes and Other Non-Current Liabilities | 3,936 | 3,898 | |
Total Liabilities | 16,300 | 18,137 | |
Shareholders' Equity: | |||
Common Stock | 1,998 | 1,966 | |
Capital in Excess of Par Value | 182,246 | 180,211 | |
Accumulated Deficit | (77,709) | (82,894) | |
Accumulated Other Comprehensive Loss | (2,473) | (1,611) | |
Treasury Stock | (18,469) | (18,469) | |
Total Ultralife Equity | 85,593 | 79,203 | |
Non-Controlling Interest | (97) | (154) | |
Total Shareholders’ Equity | 85,496 | 79,049 | |
Total Liabilities and Shareholders' Equity | $101,796 | $97,186 | |
ULTRALIFE CORPORATION AND SUBSIDIARIES | |||||||
CONSOLIDATED STATEMENTS OF INCOME | |||||||
(In Thousands Except Per Share Amounts) | |||||||
(Unaudited) | |||||||
Three-Month Periods Ended | Nine-Month Periods Ended | ||||||
September | October | September | October | ||||
30, | 1, | 30, | 1, | ||||
2018 | 2017 | 2018 | 2017 | ||||
Revenues: | |||||||
Battery & Energy Products | $17,289 | $18,616 | $52,344 | $52,977 | |||
Communications Systems | 3,041 | 2,431 | 13,919 | 10,045 | |||
Total Revenues | 20,330 | 21,047 | $66,263 | $63,022 | |||
Cost of Products Sold: | |||||||
Battery & Energy Products | 12,587 | 13,430 | 37,680 | 38,119 | |||
Communications Systems | 1,702 | 1,362 | 8,710 | 5,537 | |||
Total Cost of Products Sold | 14,289 | 14,792 | 46,390 | 43,656 | |||
Gross Profit | 6,041 | 6,255 | 19,873 | 19,366 | |||
Operating Expenses: | |||||||
Research and Development | 1,099 | 1,355 | 3,417 | 3,678 | |||
Selling, General and Administrative | 3,442 | 3,637 | 10,968 | 11,262 | |||
Total Operating Expenses | 4,541 | 4,992 | 14,385 | 14,940 | |||
Operating Income | 1,500 | 1,263 | 5,488 | 4,426 | |||
Other (Income) Expense | (21) | 58 | 27 | 200 | |||
Income Before Income Tax Provision | 1,521 | 1,205 | 5,461 | 4,226 |
|||
Income Tax Provision | 86 | 104 | 219 | 370 | |||
Net Income | 1,435 | 1,101 | 5,242 | 3,856 | |||
Net Income Attributable to Non-Controlling Interest | 27 | 3 | 57 | 8 | |||
Net Income Attributable to Ultralife Corporation | $1,408 | $1,098 | $5,185 | $3,848 | |||
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic | $.09 | $.07 | $.33 | $.25 | |||
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted | $.09 | $.07 | $.32 | $.24 | |||
Weighted Average Shares Outstanding – Basic | 15,952 | 15,564 | 15,859 | 15,495 | |||
Weighted Average Shares Outstanding – Diluted | 16,523 | 15,971 | 16,407 | 15,818 | |||
Non-GAAP Financial Measure – Adjusted EBITDA
In evaluating our business, we consider and use Adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define Adjusted EBITDA as net income attributable to
ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(In Thousands)
(Unaudited)
Three-Month Periods Ended | Nine-Month Periods Ended | ||||||
September 30, | October 1, | September 30, | October 1, | ||||
2018 | 2017 | 2018 | 2017 | ||||
Net Income Attributable to Ultralife Corporation | $1,408 | $1,098 | $5,185 | $3,848 | |||
Adjustments: | |||||||
Interest and Financing Expense, Net | 13 | 38 | 67 | 147 | |||
Income Tax Provision | 86 | 104 | 219 | 370 | |||
Depreciation Expense | 496 | 497 | 1,476 | 1,507 | |||
Amortization of Intangible Assets and Financing Fees | 106 | 115 | 327 | 357 | |||
Stock-Based Compensation Expense | 363 | 133 | 707 | 529 | |||
Adjusted EBITDA | $2,472 | $1,985 | $7,981 | $6,758 | |||
Company Contact: Ultralife Corporation Philip A. Fain (315) 210-6110 pfain@ulbi.com |
Investor Relations Contact: LHA Jody Burfening (212) 838-3777 jburfening@lhai.com |
|
Source: Ultralife Corporation